Lorglumide sodium salt
Lorglumide sodium salt structure
|
Common Name | Lorglumide sodium salt | ||
|---|---|---|---|---|
| CAS Number | 1021868-76-7 | Molecular Weight | 481.388 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H31Cl2N2NaO4 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
|
Different downstream signalling of CCK1 receptors regulates distinct functions of CCK in pancreatic beta cells.
Br. J. Pharmacol. 172 , 5050-67, (2015) Cholecystokinin (CCK) is secreted by intestinal I cells and regulates important metabolic functions. In pancreatic islets, CCK controls beta cell functions primarily through CCK1 receptors, but the signalling pathways downstream of these receptors in pancreat... |
|
|
Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse.
Peptides 16(7) , 1229-34, (1995) Various doses of sulfated cholecystokinin octapeptide (CCK-8s) injected intracerebroventricularly (ICV) alone did not show any antinociceptive effect. CCK-8s (0.01-1 ng) pretreated ICV for 10 min dose-dependently attenuated the inhibition of the tail flick re... |
|
|
Expression of the transcription factor Egr-1 in pancreatic acinar cells following stimulation of cholecystokinin or Gαq-coupled designer receptors.
Cell Physiol. Biochem. 33(5) , 1411-25, (2014) BACKGOUND/AIMS: The injection of cerulein, an analogue of the pancreatic secretagogue cholecystokinin (CCK), induces acute pancreatitis in mice that is accompanied by the synthesis of the transcription factor Egr-1. The signaling cascade that connects cerulei... |
|
|
Identification of N-arachidonylglycine, U18666A, and 4-androstene-3,17-dione as novel insulin Secretagogues.
Biochem. Biophys. Res. Commun. 333(3) , 778-86, (2005) The glucose-induced insulin secretion is fine-tuned by numerous factors. To systematically identify insulinotropic factors, we optimized a primary beta-cell-based functional assay to monitor intracellular Ca2+ flux ([Ca2+]i). By this assay system, we successf... |
|
|
Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
Arzneimittelforschung 37 , 1265-1268, (1987) Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists. The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affin... |
|
|
Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.
Br. J. Pharmacol. 102 , 391-395, (1991) 1. Three recently described non-peptide cholecystokinin (CCK) antagonists (devazepide, lorglumide, loxiglumide) have been studied for their antagonism of the contraction to cholecystokinin-octapeptide (CCK-OP) in human alimentary muscle and guinea-pig intesti... |
|
|
The role of brain-gut peptides in the control of sodium appetite.
Ann. N. Y. Acad. Sci. 897 , 192-197, (1999) Ingestion of food and fluid stimulates release of a number of peptides from the gastrointestinal system. These peptides are recognized to act as neurotransmitters/neuromodulators and act at both peripheral and central receptors. Many studies indicate that the... |